Perspective Therapeutics, Inc. (NYSE:CATX) Receives $12.75 Average Price Target from Brokerages

Shares of Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) have received a consensus recommendation of "Buy" from the eleven ratings firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $12.75.

A number of equities research analysts have issued reports on CATX shares. Royal Bank of Canada lowered their price target on Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating on the stock in a research report on Thursday, March 27th. Truist Financial lowered their target price on Perspective Therapeutics from $21.00 to $10.00 and set a "buy" rating on the stock in a report on Monday, April 7th. Wedbush reiterated an "outperform" rating and set a $11.00 price target on shares of Perspective Therapeutics in a report on Wednesday, March 26th. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research note on Tuesday, March 4th. Finally, Scotiabank started coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They set a "sector outperform" rating and a $15.00 target price for the company.

Insider Activity at Perspective Therapeutics

In other Perspective Therapeutics news, Director Robert F. Williamson III bought 38,145 shares of Perspective Therapeutics stock in a transaction dated Monday, March 31st. The shares were acquired at an average cost of $2.14 per share, with a total value of $81,630.30. Following the acquisition, the director now directly owns 108,982 shares of the company's stock, valued at $233,221.48. The trade was a 53.85 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Johan M. Spoor bought 22,026 shares of the firm's stock in a transaction dated Friday, March 28th. The shares were acquired at an average price of $2.24 per share, for a total transaction of $49,338.24. Following the acquisition, the chief executive officer now directly owns 59,383 shares of the company's stock, valued at approximately $133,017.92. The trade was a 58.96 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 115,696 shares of company stock valued at $256,344 in the last 90 days. 3.52% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CATX. Millennium Management LLC bought a new position in shares of Perspective Therapeutics in the fourth quarter worth about $4,132,000. Octagon Capital Advisors LP boosted its stake in shares of Perspective Therapeutics by 62.1% in the 4th quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company's stock valued at $7,352,000 after purchasing an additional 882,528 shares during the last quarter. Affinity Asset Advisors LLC grew its position in shares of Perspective Therapeutics by 160.0% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company's stock worth $4,147,000 after buying an additional 800,000 shares during the period. Two Sigma Investments LP bought a new stake in shares of Perspective Therapeutics during the fourth quarter worth approximately $2,075,000. Finally, Velan Capital Investment Management LP acquired a new position in Perspective Therapeutics in the fourth quarter valued at approximately $1,595,000. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Price Performance

Shares of Perspective Therapeutics stock traded up $0.02 on Tuesday, reaching $2.47. The stock had a trading volume of 339,396 shares, compared to its average volume of 1,023,553. The business's 50-day moving average price is $2.29 and its two-hundred day moving average price is $4.51. Perspective Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $19.05.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.